Transposable Element Cancer Vaccine Discovery Framework
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapies, such as checkpoint blockade therapy, have limited effectiveness due to the inability to predict which patients will respond, and the high cost and complexity of personalized vaccines based on private mutations, necessitating the development of a more widespread and affordable approach.
Innovation Solution
A computational framework for identifying and utilizing public antigens from transposable elements, specifically L1HS, which are overexpressed in cancer cells but not in healthy cells, to create personalized cancer vaccines, using RNA-seq and mass spectrometry data to select candidate antigens for vaccine development.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If personalized cancer vaccines based on private mutations are used, then the antitumor immune response is enhanced, but the cost and complexity increase prohibitively
Solution Approach 1:
The patent identifies transposable elements (TEs) as universal cancer antigens that are overexpressed across multiple cancer types and patients. By targeting these shared antigens rather than private mutations, the vaccine can be designed with broad applicability across different cancer patients while maintaining personalized customization through selection of specific TE antigens relevant to each patient's tumor profile.
Solution Approach 2:
The patent shifts the approach from targeting private mutations to targeting transposable element expression levels. By measuring and selecting based on TE expression parameters from RNA-seq data, the system creates a more scalable and cost-effective personalized vaccine approach that maintains effectiveness while reducing complexity.
2Reliability
If personalized cancer vaccines based on private mutations are used, then the antitumor immune response is enhanced, but the cost increases prohibitively
Solution Approach 1:
The patent identifies transposable elements (TEs) as universal cancer antigens that are overexpressed across multiple cancer types and patients. By targeting these shared antigens rather than private mutations, the vaccine can be designed with broad applicability across different cancer patients while maintaining personalized customization through selection of specific TE antigens relevant to each patient's tumor profile.
Solution Approach 2:
The patent uses computational frameworks to predict and identify TE antigens before vaccine production, allowing for pre-screening and selection of the most promising candidates. This virtual modeling approach reduces the need for extensive experimental testing and customization for each patient, thereby reducing overall development costs.
3Reliability
If current cancer immunotherapies are used, then some patients respond, but it is difficult to predict which patients will respond
Solution Approach 1:
The patent incorporates measurement of transposable element expression levels in patient tumors as a predictive biomarker. By quantifying TE expression through RNA-seq analysis, the system provides feedback about which patients are most likely to benefit from TE-targeted vaccination, enabling better prediction of treatment response before therapy initiation.
Solution Approach 2:
The patent replaces traditional mutation-based predictive biomarkers with transposable element expression analysis. This substitution allows for a more comprehensive and accurate prediction of treatment response by capturing the dynamic expression state of cancer cells rather than relying on static genetic mutations.
Data Source
AI summary
Candidate cancer antigens are identified using transposable elements. Differential expression levels are determined for proteins using baseline expression levels (using measurements of healthy tissue) and tumor expression levels (using measurements of tumor tissue). Protein(s) having a differential expression level greater than a threshold are selected. Cancer vaccine(s) are generated for the selected cancer antigens (s). Particular cancer vaccine(s) are selected for a patient based on differential expression levels for proteins using baseline expression levels of the patient and tumor expression levels of the patient. A vaccine for protein(s) having a differential expression level greater than a threshold can be selected. A microarray can be used for the measurements of the patient. A first array of probes can hybridize to RNA from transposable elements. A second array of probes can hybridize to RNA of different MHC haplotypes. A third array of probes can hybridize to RNA of different APOBEC genotypes.